Literature DB >> 33669698

The Correlation of Mutations and Expressions of Genes within the PI3K/Akt/mTOR Pathway in Breast Cancer-A Preliminary Study.

Przemysław Kołodziej1, Marcin Nicoś2, Paweł A Krawczyk2, Jacek Bogucki3, Agnieszka Karczmarczyk4, Daniel Zalewski1, Tomasz Kubrak5, Elżbieta Kołodziej6, Anna Makuch-Kocka7, Barbara Madej-Czerwonka8,9, Bartosz J Płachno10, Janusz Kocki6, Anna Bogucka-Kocka1.   

Abstract

There is an urgent need to seek new molecular biomarkers helpful in diagnosing and treating breast cancer. In this elaboration, we performed a molecular analysis of mutations and expression of genes within the PI3K/Akt/mTOR pathway in patients with ductal breast cancer of various malignancy levels. We recognized significant correlations between the expression levels of the studied genes. We also performed a bioinformatics analysis of the data available on the international database TCGA and compared them with our own research. Studies on mutations and expression of genes were conducted using High-Resolution Melt PCR (HRM-PCR), Allele-Specific-quantitative PCR (ASP-qPCR), Real-Time PCR molecular methods in a group of women with ductal breast cancer. Bioinformatics analysis was carried out using web source Ualcan and bc-GenExMiner. In the studied group of women, it was observed that the prevalence of mutations in the studied PIK3CA and AKT1 genes was 29.63%. It was stated that the average expression level of the PIK3CA, PIK3R1, PTEN genes in the group of breast cancer patients is lower in comparison to the control group, while the average expression level of the AKT1 and mTOR genes in the studied group was higher in comparison to the control group. It was also indicated that in the group of patients with mutations in the area of the PIK3CA and AKT1 genes, the PIK3CA gene expression level is statistically significantly lower than in the group without mutations. According to our knowledge, we demonstrate, for the first time, that there is a very strong positive correlation between the levels of AKT1 and mTOR gene expression in the case of patients with mutations and without mutations.

Entities:  

Keywords:  PI3K/Akt/mTOR pathway; biomarkers; breast cancer; expressions of genes; mutations; therapeutic targets

Mesh:

Substances:

Year:  2021        PMID: 33669698      PMCID: PMC7922286          DOI: 10.3390/ijms22042061

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  64 in total

Review 1.  A new mutational AKTivation in the PI3K pathway.

Authors:  Joan Brugge; Mien-Chie Hung; Gordon B Mills
Journal:  Cancer Cell       Date:  2007-08       Impact factor: 31.743

2.  Association of PIK3CA Mutation Status before and after Neoadjuvant Chemotherapy with Response to Chemotherapy in Women with Breast Cancer.

Authors:  Hua Yuan; Jiuan Chen; Yiqiang Liu; Tao Ouyang; Jinfeng Li; Tianfeng Wang; Zhaoqing Fan; Tie Fan; Benyao Lin; Yuntao Xie
Journal:  Clin Cancer Res       Date:  2015-05-15       Impact factor: 12.531

3.  Comparison of Three Real-Time PCR Assays for the Detection of PIK3CA Somatic Mutations in Formalin-Fixed Paraffin Embedded Tissues of Patients with Breast Carcinomas.

Authors:  A Lambert; J Salleron; M Lion; M Rouyer; N Lozano; A Leroux; J L Merlin; Alexandre Harlé
Journal:  Pathol Oncol Res       Date:  2018-11-13       Impact factor: 3.201

4.  Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer.

Authors:  E Razis; M Bobos; V Kotoula; A G Eleftheraki; H P Kalofonos; K Pavlakis; P Papakostas; G Aravantinos; G Rigakos; I Efstratiou; K Petraki; D Bafaloukos; I Kostopoulos; D Pectasides; K T Kalogeras; D Skarlos; G Fountzilas
Journal:  Breast Cancer Res Treat       Date:  2011-05-19       Impact factor: 4.872

5.  PIK3CA Mutations Detected in Patients with Central Nervous System Metastases of Non-small Cell Lung Cancer.

Authors:  Marcin Nicoś; Paweł Krawczyk; Tomasz Powrózek; Paulina Szudy; Bożena Jarosz; Marek Sawicki; Justyna Szumiło; Tomasz Trojanowski; Janusz Milanowski
Journal:  Anticancer Res       Date:  2016-05       Impact factor: 2.480

Review 6.  The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers.

Authors:  Elisavet Paplomata; Ruth O'Regan
Journal:  Ther Adv Med Oncol       Date:  2014-07       Impact factor: 8.168

7.  Prevalence of NRAS, PTEN and AKT1 gene mutations in the central nervous system metastases of non-small cell lung cancer.

Authors:  Marcin Nicoś; Paweł Krawczyk; Bożena Jarosz; Marek Sawicki; Tomasz Trojanowski; Janusz Milanowski
Journal:  Brain Tumor Pathol       Date:  2017-01-17       Impact factor: 3.298

8.  Prevalence and spectrum of AKT1, PIK3CA, PTEN and TP53 somatic mutations in Chinese breast cancer patients.

Authors:  Guoli Li; Xinwu Guo; Ming Chen; Lili Tang; Hui Jiang; Julia X Day; Yueliang Xie; Limin Peng; Xunxun Xu; Jinliang Li; Shouman Wang; Zhi Xiao; Lizhong Dai; Jun Wang
Journal:  PLoS One       Date:  2018-09-13       Impact factor: 3.240

9.  Expression of PIK3CA, PTEN mRNA and PIK3CA mutations in primary breast cancer: association with lymph node metastases.

Authors:  Irina Palimaru; Anja Brügmann; Marie Kim Wium-Andersen; Ebba Nexo; Boe Sandahl Sorensen
Journal:  Springerplus       Date:  2013-09-16

10.  Association of phosphatase and tensin homolog low and phosphatidylinositol 3-kinase catalytic subunit alpha gene mutations on outcome in human epidermal growth factor receptor 2-positive metastatic breast cancer patients treated with first-line lapatinib plus paclitaxel or paclitaxel alone.

Authors:  Binghe Xu; Zhongzhen Guan; Zhenzhou Shen; Zhongshen Tong; Zefei Jiang; Junlan Yang; Michelle DeSilvio; Mark Russo; Meggan Leigh; Catherine Ellis
Journal:  Breast Cancer Res       Date:  2014-07-24       Impact factor: 6.466

View more
  1 in total

1.  Platelet-Derived miR-126-3p Directly Targets AKT2 and Exerts Anti-Tumor Effects in Breast Cancer Cells: Further Insights in Platelet-Cancer Interplay.

Authors:  Matteo Sibilano; Valentina Tullio; Gaspare Adorno; Isabella Savini; Valeria Gasperi; Maria Valeria Catani
Journal:  Int J Mol Sci       Date:  2022-05-13       Impact factor: 6.208

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.